DR30318, a novel tri-specific T cell engager for Claudin 18.2 positive cancers immunotherapy
Cancer Immunology, Immunotherapy · 2024
DOI: 10.1007/s00262-024-03673-x ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2024. Verfasst von Zhe Ma und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Drug Metabolism and Pharmaceutical Analysis, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, Zhejiang Provinc…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Stomach Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Zhejiang Provincial Ten Thousand Plan for Young Top Talents, The National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Claudin 18.2 (CLDN18.2) is a highly anticipated target for solid tumor therapy, especially in advanced gastric carcinoma and pancreatic carcinoma. The T cell engager targeting CLDN18.2 represents a compelling strategy for enhancing anti-cancer efficacy.
Methods
Based on the in-house screened anti-CLDN18.2 VHH, we have developed a novel tri-specific T cell engager targeting CLDN18.2 for gastric and pancreatic cancer immunotherapy. This tri-specific antibody was designed with binding to CLDN18.2, human serum albumin (HSA) and CD3 on T cells.
Results
The DR30318 demonstrated binding affinity to CLDN18.2, HSA and CD3, and exhibited T cell-dependent cellular cytotoxicity (TDCC) activity in vitro. Pharmacokinetic analysis revealed a half-life of 22.2–28.6 h in rodents and 41.8 h in cynomolgus monkeys, respectively. The administration of DR30318 resulted in a slight increase in the levels of IL-6 and C-reactive protein (CRP) in cynomolgus monkeys. Furthermore, after incubation with human PBMCs and CLDN18.2 expressing cells, DR30318 induced TDCC activity and the production of interleukin-6 (IL-6) and interferon-gamma (IFN-γ). Notably, DR30318 demonstrated significant tumor suppression effects on gastric cancer xenograft models NUGC4/hCLDN18.2 and pancreatic cancer xenograft model BxPC3/hCLDN18.2 without affecting the body weight of mice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Drug Metabolism and Pharmaceutical Analysis, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, Zhejiang Province, China.
- Department of Innovative Drug Discovery and Development, Zhejiang Doer Biologics Co., Ltd., Hangzhou, 310058, Zhejiang Province, China.
- Jinhua Institute of Zhejiang University, Jinhua, 321036, China.
- Department of Innovative Drug Discovery and Development, Zhejiang Doer Biologics Co., Ltd., Hangzhou, 310058, Zhejiang Province, China. yanshanhuang@doerbio.com.
- Institute of Drug Metabolism and Pharmaceutical Analysis, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, Zhejiang Province, China. yuls@zju.edu.cn.
- National Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, Hangzhou, 310058, China. yuls@zju.edu.cn.
Förderung
- Zhejiang Provincial Ten Thousand Plan for Young Top Talents
- The National Natural Science Foundation of China
Zitieren
APA
Ma, Z., Zhou, Z., Duan, W., Yao, G., Sheng, S., Zong, S., Zhang, X., Li, C., Liu, Y., Ou, F., Dahar, M. R., Huang, Y., & Yu, L. (2024). DR30318, a novel tri-specific T cell engager for Claudin 18.2 positive cancers immunotherapy. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03673-x
Vancouver
Ma Z, Zhou Z, Duan W, Yao G, Sheng S, Zong S, et al. DR30318, a novel tri-specific T cell engager for Claudin 18.2 positive cancers immunotherapy. Cancer Immunology, Immunotherapy. 2024. doi:10.1007/s00262-024-03673-x
BibTeX
@article{Ma2024,
author = {Ma, Zhe and Zhou, Zhenxing and Duan, Wenwen and Yao, Gaofeng and Sheng, Shimei and Zong, Sidou and Zhang, Xin and Li, Changkui and Liu, Yuanyuan and Ou, Fengting and Dahar, Maha Raja and Huang, Yanshan and Yu, Lushan},
title = {DR30318, a novel tri-specific T cell engager for Claudin 18.2 positive cancers immunotherapy},
journal = {Cancer Immunology, Immunotherapy},
year = {2024},
doi = {10.1007/s00262-024-03673-x}
}
EUVIMED